RTA 15mg GLP 3

RTA 15mg GLP 3DISCLAIMER: This product is sold strictly for laboratory research purposes only. It is not intended for human consumption or medical use. By purchasing, you agree to use this product in compliance with all applicable laws and regulations. Peptide Fountain assumes no responsibility for misuse, and reserves the right to deny sale to any individual suspected of improper use. Reta (RTA) is a peptide with the following amino acid sequence

DISCLAIMER:

This product is sold strictly for laboratory research purposes only. It is not intended for human consumption or medical use. By purchasing, you agree to use this product in compliance with all applicable laws and regulations. Peptide Fountain assumes no responsibility for misuse, and reserves the right to deny sale to any individual suspected of improper use.

Reta (RTA) is a peptide with the following amino acid sequence

YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³

where letters with superscripted numbers refer to the following chemical modifications:

• A¹ – 2-aminoisobutyric acid (Aib).
• L² – leucine modified with an α-methyl substituent (MeL, 2-methylleucine).
• S³ – L-serinamide (L-serine with the carboxylic acid group replaced with a carboxamide).
• K⁴ – L-lysine with the amino group at position 6 modified with a side chain; specifically, (AEEA)-(γ-Glu)-(C20 diacid) (where AEEA is 2-[2-(2-aminoethoxy)ethoxy]acetic acid, commonly used as a spacer group in synthetic peptides).

Preclinical studies suggest that Reta (RTA) may influence obesity-associated cancer progression. Reta (RTA)-induced weight loss reduced tumor engraftment, delayed tumor onset, and significantly attenuated tumor growth in pancreatic and lung cancer models, with greater tumor suppression than the GLP-1 receptor agonist SEMA; antitumor effects persisted despite partial weight regain and were associated with durable systemic and tumor immune reprogramming.